



GattaCo Accepted Into Premier Pediatric MedTech Accelerator

Murrieta, CA, 12/17/2020 — GattaCo announced today that it has been accepted into The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP).

"GattaCo's small blood sample collection and purification technology is ideal for pediatric clinical diagnostic testing, eliminating a venipuncture for a wide variety of blood tests, enabling a new generation of point of care diagnostic devices, and simplifying pediatric clinical trials," said Dr. Michael McNeely, GattaCo's President and CEO. "We are delighted to be accepted into this outstanding organization and trust the opportunity to engage with such a substantial group of pediatric healthcare institutions and physicians will help us direct our development efforts toward doing the most good," he continued.

"We are excited about GattaCo's ability to simplify the collection, preparation, and purification of blood samples. This could have a significant impact in pediatrics, where venipuncture can sometimes be difficult or traumatic, and minimizing the total amount of blood drawn is always important." stated Dr. Juan Espinoza, Director and Principal Investigator of CTIP.

About CTIP

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is an FDA-funded pediatric MedTech accelerator centered at Children's Hospital Los Angeles. Our goal is to facilitate the development, production, and distribution of pediatric medical devices by identifying companies working in the space and providing advice, networking, and direct and indirect financial support on the road to commercialization. For more information about CTIP please email info@westcoastctip.org, or visit www.westcoastctip.org

About GattaCo

GattaCo, a young Southern California start-up company, has developed new technologies and products addressing billion-dollar bottlenecks in healthcare, specifically the ability to de-centralize clinical lab testing by simplifying the most challenging component of testing, which is sample preparation. GattaCo recently launched its new A-PON™ Kit, a home sample collection kit that automatically separates high-purity plasma from finger-stick capillary blood. The A-PON Kit eliminates the need for phlebotomy, blood tubes, centrifuges, etc., currently needed for the majority of blood tests, including COVID-19 antibody tests. The plasma produced by the A-PON Kit can be dispensed into a tube and sent to a lab for analysis, or it can be dispensed into a rapid diagnostic test for immediate results. GattaCo is also developing a pediatric-focused mini-PON™ Kit, similar to the A-PON device but requiring only a single drop of blood, and automatically separating enough plasma useful for many pediatric and neonatal testing needs. For more information about GattaCo please email info@gattaco.com, or visit www.gattaco.com